eCQM Title

Safe Use of Opioids - Concurrent Prescribing

eCQM Identifier (Measure Authoring Tool)

506

eCQM Version Number

5.0.000

NQF Number

3316e

GUID

33b40c00-909a-4490-8093-999fbcdc3480

Measurement Period

January 1, 20XX through December 31, 20XX

Measure Steward

Centers for Medicare & Medicaid Services (CMS)

Measure Developer

Mathematica

Endorsed By

National Quality Forum

Description

Proportion of inpatient hospitalizations for patients 18 years of age and older prescribed, or continued on, two or more opioids or an opioid and benzodiazepine concurrently at discharge

Limited proprietary coding is contained in the Measure specifications for user convenience. Users of proprietary code sets should obtain all necessary licenses from the owners of the code sets. Mathematica disclaims all liability for use or accuracy of any third party codes contained in the specifications.

CPT(R) contained in the measure specifications is copyright 2004-2021 American Medical Association. LOINC(R) copyright 2004-2021 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2021 International Health Terminology Standards Development Organisation. ICD-10 copyright 2021 World Health Organization. All Rights Reserved.

Disclaimer

These performance measures are not clinical guidelines, do not establish a standard of medical care, and have not been tested for all potential applications.

THE MEASURES AND SPECIFICATION ARE PROVIDED AS IS WITHOUT WARRANTY OF ANY KIND.

Due to technical limitations, registered trademarks are indicated by (R) or [R] and unregistered trademarks are indicated by (TM) or [TM].

Measure Scoring

Proportion

Measure Type

Process

Stratification

None

Risk Adjustment

None

Rate Aggregation

None

Rationale

Unintentional opioid overdose fatalities have become a major public health concern in the United States (Rudd et al., 2016). Reducing the number of unintentional overdoses has become a priority for numerous federal organizations including, but not limited to, the Centers for Disease Control and Prevention (CDC), the Federal Interagency Workgroup for Opioid Adverse Drug Events, and the Substance Abuse and Mental Health Services Administration. 

Concurrent prescriptions of opioids or opioids and benzodiazepines places patients at a greater risk of unintentional overdose due to the increased risk of respiratory depression (Dowell, Haegerich, & Chou, 2016). An analysis of national prescribing patterns shows that more than half of patients who received an opioid prescription in 2009 had filled another opioid prescription within the previous 30 days (National Institute on Drug Abuse, 2011). Studies of multiple claims and prescription databases have shown that between 5%-15% of patients receive concurrent opioid prescriptions and 5%-20% of patients receive concurrent opioid and benzodiazepine prescriptions across various settings (Liu et al., 2013; Mack et al., 2015, Park et al., 2015). Patients who have multiple opioid prescriptions have an increased risk for overdose (Jena et al., 2014). Rates of fatal overdose are ten times higher in patients who are co-dispensed opioid analgesics and benzodiazepines than opioids alone (Dasgupta et al., 2015). The number of opioid overdose deaths involving benzodiazepines increased 14% on average each year from 2006 to 2011, while the number of opioid analgesic overdose deaths not involving benzodiazepines did not change significantly (Jones & McAninch, 2015). Furthermore, concurrent use of benzodiazepines with opioids was prevalent in 31%-51% of fatal overdoses (Dowell, Haegerich, & Chou, 2016). One study found that eliminating concurrent use of opioids and benzodiazepines could reduce the risk of opioid overdose-related emergency department (ED) and inpatient visits by 15% and potentially could have prevented an estimated 2,630 deaths related to opioid painkiller overdoses in 2015 (Sun et al., 2017). 

A study on The Opioid Safety Initiative in the Veterans Health Administration (VHA), which includes an opioid and benzodiazepine concurrent prescribing measure that this measure is based on, was associated with a decrease of 20.67% overall and 0.86% patients per month (781 patients per month) receiving concurrent benzodiazepine with an opioid among all adult VHA patients who filled outpatient opioid prescriptions from October 2012 to September 2014 (Lin et al., 2017).

Adopting a measure that calculates the proportion of patients with two or more opioids or opioids and benzodiazepines concurrently has the potential to reduce preventable mortality and reduce the costs associated with adverse events related to opioid use by (1) encouraging providers to identify patients with concurrent prescriptions of opioids or opioids and benzodiazepines and (2) discouraging providers from prescribing two or more opioids or opioids and benzodiazepines concurrently.

Clinical Recommendation Statement

The 2016 CDC Guideline for Prescribing Opioids for Chronic Pain also recommends that:
- "Clinicians should avoid prescribing opioids and benzodiazepines concurrently whenever possible. Clinicians should communicate with others managing the patient to discuss the patient's needs, prioritize patient goals, weigh risks of concurrent benzodiazepine and opioid exposure, and coordinate care."
- "Clinicians should check the PDMP for concurrent controlled medications prescribed by other clinicians and should consider involving pharmacists and pain specialists as part of the management team when opioids are co-prescribed with other central nervous system depressants."
- "Experts emphasized that clinicians should communicate with mental health professionals managing the patient to discuss the patient's needs, prioritize patient goals, weigh risks of concurrent benzodiazepine and opioid exposure, and coordinate care."

In addition to the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain, opioid prescribing guidelines issued by various state agencies and professional societies for various settings agree with the recommendation to avoid concurrently prescribing opioids (AAEM, WAMDG) and opioids and benzodiazepines (WAMDG, ASIPP, NYC DOHMH) whenever possible as the combination of these medications may potentiate opioid-induced respiratory depression.

The CDC Guideline for Prescribing Opioids for Chronic Pain (Dowell, 2016) also recommends that for patients found to have multiple opioid prescriptions clinicians should:
- "Discuss information from the PDMP with their patient and confirm that the patient is aware of the additional prescriptions."
- "Discuss safety concerns, including increased risk for respiratory depression and overdose, with patients found to be receiving opioids from more than one prescriber or receiving medications that increase risk when combined with opioids and consider offering naloxone."
- "Discuss safety concerns with other clinicians who are prescribing controlled substances for their patient. Ideally clinicians should first discuss concerns with their patient and inform him or her that they plan to coordinate care with the patient's other prescribers to improve the patient's safety."

Improvement Notation

Improvement noted as a decrease in the rate

Reference

Reference Type: CITATION

Reference Text: 'American Academy of Emergency Medicine (AAEM). (2013). Emergency department opioid-prescribing guidelines for the treatment of non-cancer-related pain. Retrieved from https://www.aaem.org/UserFiles/file/Emergency-Department-Opoid-Prescribing-Guidelines.pdf'

Reference

Reference Type: CITATION

Reference Text: 'American Society of Interventional Pain Physicians (ASIPP). (2012). Guidelines for responsible opioid prescribing in chronic noncancer pain. Retrieved from https://pubmed.ncbi.nlm.nih.gov/22786449/'

Reference

Reference Type: CITATION

Reference Text: 'Dasgupta, N., Jonsson Funk, M., Proescholdbell, S., et al. (2015, September). Cohort study of the impact of high-dose opioid analgesics on overdose mortality. Pain Medicine. Retrieved from http://onlinelibrary.wiley.com/doi/10.1111/pme.12907/abstract  '

Reference

Reference Type: CITATION

Reference Text: 'Dowell, D., Haegerich, T., & Chou, R. (2016). CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR Recommendations and Reports, 65. Retrieved from http://www.cdc.gov/media/dpk/2016/dpk-opioid-prescription-guidelines.html'

Reference

Reference Type: CITATION

Reference Text: 'Geller, A. I., Dowell, D., Lovegrove, M. C., Mcaninch, J. K., Goring, S. K., Rose, K. O., … Budnitz, D. S. (2019). U.S. Emergency Department Visits Resulting From Nonmedical Use of Pharmaceuticals, 2016. American Journal of Preventive Medicine, 56(5), 639–647. https://doi.org/10.1016/j.amepre.2018.12.009'

Reference

Reference Type: CITATION

Reference Text: 'Herzig, S., Rothberg, M., Cheung, M., et al. (2014). Opioid utilization and opioid-related adverse events in nonsurgical patients in U.S. hospitals. Journal of Hospital Medicine, 9(2), 73-81.'

Reference

Reference Type: CITATION

Reference Text: 'Jena, A., Goldman, D., Schaeffer, L. D., et al. (2014). Opioid prescribing by multiple providers in Medicare: Retrospective observational study of insurance claims. BMJ, 348, g1393. DOI: 10.1136/bmj.g1393'

Reference

Reference Type: CITATION

Reference Text: 'Lin, L. A., Bohnert, A. S., Kerns, R. D., et al. (2017). Impact of the opioid safety initiative on opioid-related prescribing in veterans. Pain, 158(5), 833–839. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28240996'

Reference

Reference Type: CITATION

Reference Text: 'Liu, Y., Logan, J., Paulozzi, L., et al. (2013). Potential misuse and inappropriate prescription practices involving opioid analgesics. American Journal of Managed Care, 19(8), 648–665. Retrieved from http://www.ajmc.com/journals/issue/2013/2013-1-vol19-n8/Potential-Misuse-and-Inappropriate-Prescription-Practices-Involving-Opioid-Analgesics/'

Reference

Reference Type: CITATION

Reference Text: 'Mack, K., Zhang, K., Paulozzi, L., et al. (2015, February). Prescription practices involving opioid analgesics among Americans with Medicaid, 2010. Journal of Health Care for the Poor and Underserved, 26(1), 182–198. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365785'

Reference

Reference Type: CITATION

Reference Text: 'National Institute on Drug Abuse. (2011). Analysis of opioid prescription practices finds areas of concern. Retrieved from https://www.drugabuse.gov/news-events/news-releases/2011/04/analysis-opioid-prescription-practices-finds-areas-concern'

Reference

Reference Type: CITATION

Reference Text: 'New York City (NYC) Department of Health and Mental Hygiene (NYC DOHMH). (2013). NYC emergency department discharge opioid-prescribing guidelines. Retrieved from https://www1.nyc.gov/site/doh/providers/health-topics/opioid-prescribing-resources-for-emergency-departments.page'

Reference

Reference Type: CITATION

Reference Text: 'Park, T., Saitz, R., Ganoczy, D., et al. (2015). Benzodiazepine-prescribing patterns and deaths from drug overdose among U.S. veterans receiving opioid analgesics: Case-cohort study. BMJ, 350, h2698. Retrieved from http://www.bmj.com/content/350/bmj.h2698'

Reference

Reference Type: CITATION

Reference Text: 'Rudd, R., Aleshire, N., Zibbell, J., et al. (2016, January). Increases in drug and opioid overdose deaths—United States, 2000–2014. Morbidity and Mortality Weekly Report, 64(50), 1378–1382. Retrieved from http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6450a3.htm'

Reference

Reference Type: CITATION

Reference Text: 'Sun, E., Dixit, A., Humphreys, K., et al. (2017). Association between concurrent use of prescription opioids and benzodiazepines and overdose: Retrospective analysis. BMJ, 356, j760. Retrieved from
http://www.bmj.com/content/356/bmj.j760'

Reference

Reference Type: CITATION

Reference Text: 'U.S. Department of Veterans Affairs. (2014). Opioid safety initiative toolkit. Retrieved from https://www.va.gov/PAINMANAGEMENT/Opioid_Safety_Initiative_OSI.asp'

Reference

Reference Type: CITATION

Reference Text: 'U.S. Department of Veterans Affairs. (2016). Opioid safety initiative: Opioids (including tramadol) used in combination with benzodiazepine derivative sedatives/hypnotics. Unpublished manuscript.'

Reference

Reference Type: CITATION

Reference Text: 'Washington Agency Medical Directors’ Group (WAMDG). (2015). Interagency guideline on prescribing opioids for pain, Part II: Prescribing opioids in the acute and subacute phase. Retrieved from http://www.agencymeddirectors.wa.gov/Files/2015AMDGOpioidGuideline.pdf'

Definition

For the purpose of this measure, the following are defined as:

-Opioid: Any Schedule II or III opioid medication

-Benzodiazepine: Any Schedule IV benzodiazepine medication

-Prescribed: The intent of the measure is to capture opioid and/or benzodiazepine medications continued or ordered at discharge

-Numerator criteria: Two or more unique orders for opioids, or an opioid and benzodiazepine at discharge

Guidance

Clinician judgement, clinical appropriateness, or both may indicate concurrent prescribing of two unique opioids or an opioid and benzodiazepine is medically necessary, thus the measure is not expected to have a zero rate. 

Inpatient hospitalizations with discharge medications of a new or continuing opioid or a new or continuing benzodiazepine prescription should be included in the initial population. 

Inpatient hospitalizations with discharge medications of two or more new or continuing opioids or new or continuing opioid and benzodiazepine resulting in concurrent therapy at discharge should be included in the numerator. Each benzodiazepine and opioid included on the medication discharge list is considered a unique prescription.

The denominator population includes patients with inpatient hospitalizations and patients from Acute Hospital Care at Home programs, who are treated and billed as inpatients but receive care in their home.

This eCQM is an episode-based measure. An episode is defined as each inpatient hospitalization or encounter that ends during the measurement period.

This version of the eCQM uses QDM version 5.6. Please refer to the eCQI Resource Center (https://ecqi.healthit.gov/qdm) for more information on the QDM.

Transmission Format

TBD

Initial Population

Inpatient hospitalizations (inpatient stay less than or equal to 120 days) that end during the measurement period, where the patient is 18 years of age and older at the start of the encounter and prescribed one or more new or continuing opioid or benzodiazepine at discharge

Denominator

Initial Population

Denominator Exclusions

Inpatient hospitalizations where patients have cancer that begins prior to or during the encounter or are receiving palliative or hospice care (including comfort measures, terminal care, and dying care) during the encounter, patients discharged to another inpatient care facility, and patients who expire during the inpatient stay

Numerator

Inpatient hospitalizations where the patient is prescribed or continuing to take two or more opioids or an opioid and benzodiazepine at discharge

Numerator Exclusions

Not Applicable

Denominator Exceptions

None

Supplemental Data Elements

For every patient evaluated by this measure also identify payer, race, ethnicity and sex

Population Criteria
Definitions
Functions
Terminology
Data Criteria (QDM Data Elements)
Supplemental Data Elements
Risk Adjustment Variables

Population Criteria

Initial Population

"Inpatient Encounters with an Opioid or Benzodiazepine at Discharge"

- Denominator
  - "Initial Population"

Denominator Exclusions

/*Excludes encounters of patients with cancer or who are receiving palliative or hospice care at the time of the encounter*/
"Inpatient Encounters with an Opioid or Benzodiazepine at Discharge" InpatientEncounter
  where exists ( ["Diagnosis": "All Primary and Secondary Cancer"] Cancer
      where Cancer.prevalencePeriod overlaps InpatientEncounter.relevantPeriod
  )
    or exists ( "Inpatient Encounters with an Opioid or Benzodiazepine at Discharge" InpatientEncounter
        where exists InpatientEncounter.diagnoses Diagnosis
          where Diagnosis.code in "All Primary and Secondary Cancer"
    )
    or exists ( "Intervention Palliative or Hospice Care" PalliativeOrHospiceCare
        where Coalesce(start of Global."NormalizeInterval"(PalliativeOrHospiceCare.relevantDatetime, PalliativeOrHospiceCare.relevantPeriod), PalliativeOrHospiceCare.authorDatetime)during Global."HospitalizationWithObservation" ( InpatientEncounter )
    )
    or exists ( "Inpatient Encounters with an Opioid or Benzodiazepine at Discharge" InpatientEncounter
        where InpatientEncounter.dischargeDisposition in "Discharge To Acute Care Facility"
          or InpatientEncounter.dischargeDisposition in "Hospice Care Referral or Admission"
          or InpatientEncounter.dischargeDisposition in "Patient Expired"
    )

Numerator

/*Encounters of patients prescribed two or more opioids or an opioid and benzodiazepine at discharge.
*/
( "Inpatient Encounters with an Opioid or Benzodiazepine at Discharge" InpatientEncounter
    where ( Count(["Medication, Discharge": "Schedule II & III Opioid Medications"] Opioids
          where Opioids.authorDatetime during InpatientEncounter.relevantPeriod
          return distinct Opioids.code
      )>= 2
    )
)
  union ( "Inpatient Encounters with an Opioid or Benzodiazepine at Discharge" InpatientEncounter
      with ["Medication, Discharge": "Schedule II & III Opioid Medications"] OpioidsDischarge
        such that OpioidsDischarge.authorDatetime during InpatientEncounter.relevantPeriod
      with ["Medication, Discharge": "Schedule IV Benzodiazepines"] BenzodiazepinesDischarge
        such that BenzodiazepinesDischarge.authorDatetime during InpatientEncounter.relevantPeriod
  )

- Numerator Exclusions
  - None

- Denominator Exceptions
  - None

- Stratification
  - None

Definitions

Denominator
- - "Initial Population"

Denominator Exclusion

/*Excludes encounters of patients with cancer or who are receiving palliative or hospice care at the time of the encounter*/
"Inpatient Encounters with an Opioid or Benzodiazepine at Discharge" InpatientEncounter
  where exists ( ["Diagnosis": "All Primary and Secondary Cancer"] Cancer
      where Cancer.prevalencePeriod overlaps InpatientEncounter.relevantPeriod
  )
    or exists ( "Inpatient Encounters with an Opioid or Benzodiazepine at Discharge" InpatientEncounter
        where exists InpatientEncounter.diagnoses Diagnosis
          where Diagnosis.code in "All Primary and Secondary Cancer"
    )
    or exists ( "Intervention Palliative or Hospice Care" PalliativeOrHospiceCare
        where Coalesce(start of Global."NormalizeInterval"(PalliativeOrHospiceCare.relevantDatetime, PalliativeOrHospiceCare.relevantPeriod), PalliativeOrHospiceCare.authorDatetime)during Global."HospitalizationWithObservation" ( InpatientEncounter )
    )
    or exists ( "Inpatient Encounters with an Opioid or Benzodiazepine at Discharge" InpatientEncounter
        where InpatientEncounter.dischargeDisposition in "Discharge To Acute Care Facility"
          or InpatientEncounter.dischargeDisposition in "Hospice Care Referral or Admission"
          or InpatientEncounter.dischargeDisposition in "Patient Expired"
    )

Initial Population

"Inpatient Encounters with an Opioid or Benzodiazepine at Discharge"

Inpatient Encounter with Age Greater than or Equal to 18

Global."Inpatient Encounter" InpatientHospitalEncounter
  where AgeInYearsAt(date from start of InpatientHospitalEncounter.relevantPeriod)>= 18

Inpatient Encounters with an Opioid or Benzodiazepine at Discharge

/*Captures encounters of patients with an opioid(s), benzodiazepine, or a combination of these medications at discharge*/
"Inpatient Encounter with Age Greater than or Equal to 18" InpatientEncounter
  with ( ["Medication, Discharge": "Schedule II & III Opioid Medications"]
    union ["Medication, Discharge": "Schedule IV Benzodiazepines"] ) OpioidOrBenzodiazepineDischargeMedication
    such that OpioidOrBenzodiazepineDischargeMedication.authorDatetime during InpatientEncounter.relevantPeriod

Intervention Palliative or Hospice Care

["Intervention, Order": "Palliative or Hospice Care"]
  union ["Intervention, Performed": "Palliative or Hospice Care"]

Global.Inpatient Encounter

["Encounter, Performed": "Encounter Inpatient"] EncounterInpatient
  where "LengthInDays"(EncounterInpatient.relevantPeriod)<= 120
    and EncounterInpatient.relevantPeriod ends during day of "Measurement Period"

Numerator

/*Encounters of patients prescribed two or more opioids or an opioid and benzodiazepine at discharge.
*/
( "Inpatient Encounters with an Opioid or Benzodiazepine at Discharge" InpatientEncounter
    where ( Count(["Medication, Discharge": "Schedule II & III Opioid Medications"] Opioids
          where Opioids.authorDatetime during InpatientEncounter.relevantPeriod
          return distinct Opioids.code
      )>= 2
    )
)
  union ( "Inpatient Encounters with an Opioid or Benzodiazepine at Discharge" InpatientEncounter
      with ["Medication, Discharge": "Schedule II & III Opioid Medications"] OpioidsDischarge
        such that OpioidsDischarge.authorDatetime during InpatientEncounter.relevantPeriod
      with ["Medication, Discharge": "Schedule IV Benzodiazepines"] BenzodiazepinesDischarge
        such that BenzodiazepinesDischarge.authorDatetime during InpatientEncounter.relevantPeriod
  )

SDE Ethnicity

["Patient Characteristic Ethnicity": "Ethnicity"]

SDE Payer

["Patient Characteristic Payer": "Payer"]

SDE Race
- - ["Patient Characteristic Race": "Race"]

SDE Sex

["Patient Characteristic Sex": "ONC Administrative Sex"]

Functions

Global.HospitalizationWithObservation(Encounter "Encounter, Performed")

Encounter Visit
	let ObsVisit: Last(["Encounter, Performed": "Observation Services"] LastObs
			where LastObs.relevantPeriod ends 1 hour or less on or before start of Visit.relevantPeriod
			sort by 
			end of relevantPeriod
	),
	VisitStart: Coalesce(start of ObsVisit.relevantPeriod, start of Visit.relevantPeriod),
	EDVisit: Last(["Encounter, Performed": "Emergency Department Visit"] LastED
			where LastED.relevantPeriod ends 1 hour or less on or before VisitStart
			sort by 
			end of relevantPeriod
	)
	return Interval[Coalesce(start of EDVisit.relevantPeriod, VisitStart), 
	end of Visit.relevantPeriod]

Global.LengthInDays(Value Interval<DateTime>)

difference in days between start of Value and end of Value

Global.NormalizeInterval(pointInTime DateTime, period Interval<DateTime>)

if pointInTime is not null then Interval[pointInTime, pointInTime]
  else if period is not null then period 
  else null as Interval<DateTime>

Terminology

valueset "All Primary and Secondary Cancer" (2.16.840.1.113762.1.4.1111.161)
valueset "Discharge To Acute Care Facility" (2.16.840.1.113883.3.117.1.7.1.87)
valueset "Emergency Department Visit" (2.16.840.1.113883.3.117.1.7.1.292)
valueset "Encounter Inpatient" (2.16.840.1.113883.3.666.5.307)
valueset "Ethnicity" (2.16.840.1.114222.4.11.837)
valueset "Hospice Care Referral or Admission" (2.16.840.1.113762.1.4.1116.365)
valueset "Observation Services" (2.16.840.1.113762.1.4.1111.143)
valueset "ONC Administrative Sex" (2.16.840.1.113762.1.4.1)
valueset "Palliative or Hospice Care" (2.16.840.1.113883.3.600.1.1579)
valueset "Patient Expired" (2.16.840.1.113883.3.117.1.7.1.309)
valueset "Payer" (2.16.840.1.114222.4.11.3591)
valueset "Race" (2.16.840.1.114222.4.11.836)
valueset "Schedule II & III Opioid Medications" (2.16.840.1.113762.1.4.1111.165)
valueset "Schedule IV Benzodiazepines" (2.16.840.1.113762.1.4.1125.1)

Data Criteria (QDM Data Elements)

"Diagnosis: All Primary and Secondary Cancer" using "All Primary and Secondary Cancer (2.16.840.1.113762.1.4.1111.161)"
"Encounter, Performed: Emergency Department Visit" using "Emergency Department Visit (2.16.840.1.113883.3.117.1.7.1.292)"
"Encounter, Performed: Encounter Inpatient" using "Encounter Inpatient (2.16.840.1.113883.3.666.5.307)"
"Encounter, Performed: Observation Services" using "Observation Services (2.16.840.1.113762.1.4.1111.143)"
"Intervention, Order: Palliative or Hospice Care" using "Palliative or Hospice Care (2.16.840.1.113883.3.600.1.1579)"
"Intervention, Performed: Palliative or Hospice Care" using "Palliative or Hospice Care (2.16.840.1.113883.3.600.1.1579)"
"Medication, Discharge: Schedule II & III Opioid Medications" using "Schedule II & III Opioid Medications (2.16.840.1.113762.1.4.1111.165)"
"Medication, Discharge: Schedule IV Benzodiazepines" using "Schedule IV Benzodiazepines (2.16.840.1.113762.1.4.1125.1)"
"Patient Characteristic Ethnicity: Ethnicity" using "Ethnicity (2.16.840.1.114222.4.11.837)"
"Patient Characteristic Payer: Payer" using "Payer (2.16.840.1.114222.4.11.3591)"
"Patient Characteristic Race: Race" using "Race (2.16.840.1.114222.4.11.836)"
"Patient Characteristic Sex: ONC Administrative Sex" using "ONC Administrative Sex (2.16.840.1.113762.1.4.1)"

Supplemental Data Elements

SDE Ethnicity

["Patient Characteristic Ethnicity": "Ethnicity"]

SDE Payer

["Patient Characteristic Payer": "Payer"]

SDE Race
- - ["Patient Characteristic Race": "Race"]

SDE Sex

["Patient Characteristic Sex": "ONC Administrative Sex"]

Risk Adjustment Variables

None

Measure Set